UroGen Pharma Ltd. (URGN) intrinsic value & 10-year financials
UroGen Pharma Ltd. (URGN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 22.6% a year to $109.8M, with an average return on invested capital of -167.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $34.56
- Revenue (FY2025)
- $109.8M
- Revenue growth (10-yr CAGR)
- 22.6%
- ROIC (10-yr avg)
- -167.7%
- Free cash flow (FY2025)
- -$162.7M
URGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $109.8M | -$153.5M | — | -$162.7M | -113.7% | 171.9% |
| FY2024 | $90.4M | -$126.9M | — | -$97.1M | -107.1% | 164.9% |
| FY2023 | $82.7M | -$102.2M | — | -$76.6M | -79.2% | 124.1% |
| FY2022 | $64.4M | -$109.8M | — | -$87.8M | -122.8% | 194.7% |
| FY2021 | $48.0M | -$110.8M | — | -$85.6M | -192.1% | -1955.5% |
| FY2020 | $11.8M | -$128.5M | — | -$107.1M | -1074.2% | -142.2% |
| FY2019 | $18.0K | -$105.1M | — | -$71.3M | -608211.1% | -78.9% |
| FY2018 | $1.1M | -$75.7M | — | -$37.9M | -6842.2% | -97.3% |
| FY2017 | $8.2M | -$20.0M | — | -$9.8M | -244.5% | -47.0% |
| FY2016 | $17.5M | -$1.9M | — | $3.5M | 4.6% | -11.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
UroGen Pharma Ltd. is a consistent compounder, expanding top-line revenue at 22.6% annually over the past decade.
UroGen Pharma Ltd. has historically struggled to out-earn its cost of capital, averaging just -26.8% ROIC.
UroGen Pharma Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, UroGen Pharma Ltd. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.